Exhibit 99.1 Q3 2025 product revenue of $105.5 million reflects 15$78.2 million reflects 92% year-over-year growth; IBSRELA guidance raised, 2025 revenue expected to be between $270-275 million ® Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update XPHOZAH Q3 revenue of$27.4 million, up 9% compared to Q2 2025 ® Company announces pipeline program for next-generation NHE3 inhibitor; Potential application across multiple therapeutic a ...